To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (ENTRUST)

Inclusion Criteria: Age ≥22 years Willing to enter a lifestyle optimization period during the screening period and willing to maintain those eating and exercise habits for the duration of the study Subjects should be on stable background standard-of-care Lipid Modifying Therapy (LMT) Exclusion Criteria: Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitus as determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% at Screening. Medications for glucose management must be stable for at least 4 weeks prior to Screening Type 1 diabetes mellitus A history of symptomatic gallstone disease (unless treated with cholecystectomy), or any other ongoing symptomatic biliary disease Acute pancreatitis within 6 months prior to Screening Subjects with chronic pancreatitis Known or suspected familial chylomicronemia syndrome (FCS) (Type 1 hyperlipoproteinemia) Other inclusion and exclusion criteria may apply.